DISCLAIMER: GOLDINVESTMENTCOMPANIES.COM IS AN AFFILIATED PARTNER FOR GOLDCO PRECIOUS METALS, AUGUSTA PRECIOUS METALS, AND BIRCH GOLD GROUP, PROMOTING THEIR GOLD IRA, GOLD 401K TRANSFER AND BITCOIN IRA SERVICES AND PRODUCTS.
Sirona Biochem (TSXV:SBM) chief scientific officer Géraldine Deliencourt-Godefroy discusses the compelling results from the clinical trial of its anti-aging compound TFC 1326 and the next steps for the company in securing a licensing deal.
00:00 Introduction
00:43 TFC-1326: An accidental discovery
05:40 What transpired during the TFC-1326 clinical trial
09:58 Next steps for the company after the clinical trial
#biotech #lifesciencestocks #investing
________________________________________________________________
Investing News Network (INN)
Find out more about investing by INN @
https://investingnews.com/
Browse our 2023 outlook reports:
http://bit.ly/3JHyR1M
Follow us Facebook:
https://www.facebook.com/investing.news.your.trusted.source
Follow us on Twitter:
@INN_Resource
________________________________________________________________
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
